drugset / Trial / NCT00558961

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients

NCT00558961

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine maximum tolerated dose of Gleevec in combination with Chlorambucil in previously treated CLL patients.

Timeline

Start
2005-10
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 300 mg
Subject Imatinib Small molecule 400 mg
Subject Imatinib Small molecule 600 mg
Background Chlorambucil Other / unclassified 8 mg/m2